- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | SALT LAKE CITY - Sera Prognostics-Direktor verkauft Aktien im Wert von 769 US-Dollar | 1 | Investing.com Deutsch | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 31 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 06.11.24 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.24 | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 10.09.24 | Sera Prognostics CEO sells shares worth $189,893 | 1 | Investing.com | ||
| 08.08.24 | Sera Prognostics director sells shares worth $749 | 1 | Investing.com | ||
| 08.08.24 | Sera Prognostics CIO sells over $37k in company stock | 1 | Investing.com | ||
| 08.08.24 | Sera Prognostics executive sells $37k in company stock | 1 | Investing.com | ||
| 08.08.24 | Sera Prognostics executive sells shares worth over $32,000 | 1 | Investing.com | ||
| 07.08.24 | Sera Prognostics files $100M mixed securities shelf | 1 | Seeking Alpha | ||
| 07.08.24 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08.24 | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2024 Financial Results | 80 | PR Newswire | SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
| 08.05.24 | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2024 Financial Results | 199 | PR Newswire | SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
| 20.03.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial Results | 211 | PR Newswire | SALT LAKE CITY, March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,395 | -3,79 % | Nanorepro: "Bedeutender Schritt für die Zukunft" | Nanorepro kommt 2024 auf einen Umsatz von 4,4 Millionen Euro (Vorjahr: 3,2 Millionen Euro). Mit Corona-Tests, dem Umsatztreiber in früheren Jahren, werden dabei nur noch marginale Umsätze erzielt. Vor... ► Artikel lesen | |
| OCUGEN | 0,749 | +0,94 % | Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema | MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,130 | +0,73 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| SCORPIUS | 0,274 | +7,03 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer | DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,560 | +2,40 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,300 | +0,36 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| VAXART | 0,729 | -2,93 % | Vaxart, Inc. - 8-K, Current Report | ||
| REDHILL BIOPHARMA | 6,460 | -2,42 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IBIO | 3,065 | +1,32 % | iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio | SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,048 | -3,85 % | Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC Wainwright | ||
| MANNKIND | 5,750 | +0,14 % | MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study | WASHINGTON (dpa-AFX) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin... ► Artikel lesen | |
| ALDEYRA | 4,718 | -3,20 % | Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update | ||
| CARDIFF ONCOLOGY | 3,280 | +0,77 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial | - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control... ► Artikel lesen | |
| TRAWS PHARMA | 4,490 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu | Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention
NEWTOWN... ► Artikel lesen | |
| COHERUS | 1,196 | +1,61 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,570 Euro und damit +1,23 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.
